RxDoctor Payments Data

Syed Khurshid, MD

Internal Medicine · Orange City, FLNPI 1730147455

Payments from drug & device makers

$318in general payments, 2019–2025

Across 16 payments — averaging $19.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$95
  • Novo Nordisk$87
  • AstraZeneca$52
  • Otsuka America Pharmaceutical, Inc.$20
  • Amgen$18
  • Lundbeck LLC$17
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$318100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$318 in reported general payments places this provider in the 45th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$503,158
Medicare patients
536
Services billed
5,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$90,947
JanuviaSitagliptin Phosphate61$52,931
JardianceEmpagliflozin65$52,089
OzempicSemaglutide39$48,643
FarxigaDapagliflozin Propanediol23$23,728
MounjaroTirzepatide12$18,414
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$18,149
EntrestoSacubitril/Valsartan15$12,976
Breo ElliptaFluticasone/Vilanterol12$9,634
MyrbetriqMirabegron20$8,088
Spiriva RespimatTiotropium Bromide12$6,573
XareltoRivaroxaban18$5,822
Arnuity ElliptaFluticasone Furoate14$4,719
Rosuvastatin Calcium280$4,496
Memantine Hcl120$4,211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$90,947113 claims
Novo NordiskOzempic$87$48,64339 claims
AstraZenecaFarxiga$52$23,72823 claims
Lilly USA, LLCMounjaro$15$18,41412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Orange City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →